Over 80 % of adenomas and CRC exhibit APC mutations and a further 5–10 % are showing mutations or epigenetic changes in other WNT signalling components (e.g. β-catenin) that equally result in hyperactivation of the WNT pathway [12–14]. This evidence concerns the gene APC and adenoma.